678 related articles for article (PubMed ID: 24013900)
1. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
3. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
[TBL] [Abstract][Full Text] [Related]
4. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society.
Ahn SH; Kim HJ; Lee JW; Gong GY; Noh DY; Yang JH; Jung SS; Park HY
Breast Cancer Res Treat; 2011 Nov; 130(2):507-15. PubMed ID: 21858659
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
6. Lymph node ratio: a new feature for defining risk category of node-positive breast cancer patients.
Yang C; Liu F; Li S; Li W; Zhai L; Ren M; Li Y; Lang R; Fan Y; Zhang X; Fu L
Int J Surg Pathol; 2012 Dec; 20(6):546-54. PubMed ID: 22736300
[TBL] [Abstract][Full Text] [Related]
7. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
Kim YS; Kim JH; Yoon SM; Choi EK; Ahn SD; Lee SW; Kim JC; Yu CS; Kim HC; Kim TW; Chang HM
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):796-802. PubMed ID: 19289261
[TBL] [Abstract][Full Text] [Related]
8. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio should be considered for incorporation into staging for breast cancer.
Chagpar AB; Camp RL; Rimm DL
Ann Surg Oncol; 2011 Oct; 18(11):3143-8. PubMed ID: 21847696
[TBL] [Abstract][Full Text] [Related]
11. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients.
Schiffman SC; McMasters KM; Scoggins CR; Martin RC; Chagpar AB
J Am Coll Surg; 2011 Jul; 213(1):45-52; discussion 52-3. PubMed ID: 21601490
[TBL] [Abstract][Full Text] [Related]
12. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
13. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy.
Wu SG; Chen Y; Sun JY; Li FY; Lin Q; Lin HX; He ZY
Radiat Oncol; 2013 May; 8():119. PubMed ID: 23672513
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
15. Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.
Xiao XS; Tang HL; Xie XH; Li LS; Kong YN; Wu MQ; Yang L; Gao J; Wei WD; Xie X
Asian Pac J Cancer Prev; 2013; 14(9):5219-23. PubMed ID: 24175804
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of metastatic axillary lymph node ratio in node-positive breast cancer treated by breast conserving surgery].
Zheng Y; Chen Q; Liang Z; Jia M; Cao X
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):41-6. PubMed ID: 25877318
[TBL] [Abstract][Full Text] [Related]
17. When is a lymph node dissection a lymph node dissection? The number of lymph nodes resected in sentinel and axillary lymph node dissections.
Olaya W; Wong J; Wong J; Morgan J; Kazanjian K; Lum S
Ann Surg Oncol; 2013 Feb; 20(2):627-32. PubMed ID: 22956069
[TBL] [Abstract][Full Text] [Related]
18. Lymph node ratio as an alternative to pN staging in node-positive breast cancer.
Vinh-Hung V; Verkooijen HM; Fioretta G; Neyroud-Caspar I; Rapiti E; Vlastos G; Deglise C; Usel M; Lutz JM; Bouchardy C
J Clin Oncol; 2009 Mar; 27(7):1062-8. PubMed ID: 19164210
[TBL] [Abstract][Full Text] [Related]
19. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer.
van der Wal BC; Butzelaar RM; van der Meij S; Boermeester MA
Eur J Surg Oncol; 2002 Aug; 28(5):481-9. PubMed ID: 12217299
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
